8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
- -----------------------------

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
- -------------------------------


Date of report (Date of earliest event reported): JANUARY 20, 1997



BOSTON SCIENTIFIC CORPORATION
- ----------------------------------------------------
(Exact name of registrant as specified in charter)

Commission file number:  1-11083


DELAWARE					04-2695240
- -----------------				---------------
(State or other				         (IRS employer
 jurisdiction of				 identification no.)
 incorporation)



One Boston Scientific Place, Natick, Massachusetts	01760-1537
- --------------------------------------------------	----------
(Address of principal executive offices)               (Zip code)



Registrant's telephone number, including area code:	(508) 650-8000
                                 			---------------



















ITEM 5.	OTHER EVENTS

	On January 20, 1997, Boston Scientific Corporation
(the "Company") entered into an Agreement and Plan of Merger 
(the "Merger Agreement") by and among the Company, Target 
Therapeutics, Inc. ("Target") and Patriot Acquisition Corp., 
a Delaware corporation and a wholly owned subsidiary of the 
Company ("Merger Sub"), pursuant to which Merger Sub will 
merge (the "Merger") with and into Target.  Pursuant to 
the Merger Agreement, shareholders of Target will receive 1.07 
shares of the Company's common stock in exchange for each share 
of Target common stock.  The Merger, valued at $1.1 billion, is
expected to be accounted for as a pooling-of-interests and to 
qualify as a tax-free reorganization. 

	The Merger is expected to close during the second calendar 
quarter of 1997 and is subject to the approval of shareholders 
of Target Therapeutics and regulatory approval.  Goldman, 
Sachs & Co. is serving as financial advisors to Target Therapeutics 
and has issued a fairness opinion to the Target Therapeutics 
board of directors with respect to the proposed combination.  
Lehman Brothers is serving as financial advisors to the 
Company.  



ITEM 7.	         FINANCIAL STATEMENTS, PRO FORMA 
		FINANCIAL INFORMATION AND EXHIBITS

		Exhibit Number	         Description
		-------------------	--------------

			99.1		Press Release of Boston Scientific 
     			         	Corporation, dated January 20, 1997

























	SIGNATURES


	Pursuant to the requirements of the Securities and Exchange 
Act of 1934, the Registrant has duly caused this report to be signed on 
its behalf by the undersigned hereunto duly authorized.



Date:   February 5, 1997	     By:	 /s/  Paul W. Sandman	
                                       ----------------------------
                      			Name:    Paul W. Sandman
                      			Title:   Senior Vice President and
                      			         General Counsel

 

EX-99

Boston Scientific And Target Therapeutics
Announce Agreement To Merge

Natick, Mass. and Fremont, Calif. (January 20, 1997)--Boston
Scientific Corporation (NYSE:BSX) and Target Therapeutics, 
Inc. (NASDAQ:TGET) today jointly announced the signing 
of a definitive agreement to merge in a tax-free stock-for-stock 
transaction valued at approximately $1.1 billion.  
Under the merger agreement, unanimously approved by 
the boards of both companies, Target Therapeutics' 
stockholders would receive 1.07 shares of Boston Scientific 
common stock in exchange for each share of Target Therapeutics 
common stock.

Target Therapeutics, Inc., headquartered in Fremont, 
California, designs, develops, manufactures and markets 
catheter-based disposable and implantable medical devices 
used in minimally invasive procedures to treat neurovascular 
diseases and disorders.  The Company's products are used 
to treat diseased, ruptured or blocked blood vessels in 
the brain responsible for stroke.  One of these products, the 
Guglielmi Detachable Coil (GDC) system, is used to treat 
and prevent the rupture of cerebral aneurysms.  The GDC is 
the only device today approved by the FDA for treatment of 
inoperable or high risk intracranial aneurysms.  Stroke 
currently affects over 600,000 Americans annually and 
is the third leading cause of death in the United States.  
The Company is a global leader in interventional 
neuroradiology with over 60% of its revenues coming 
from international markets.

Commenting on the merger, Pete Nicholas, Chairman 
and Chief Executive Officer of Boston Scientific, noted, 
"Target Therapeutics has become the clear leader in the 
emerging market for minimally invasive treatment of neurovascular 
disease.  Its impressive product line and technology base 
combined with Boston Scientific's technology platform 
will represent the broadest and deepest product offering 
and technology base in the world for the less invasive 
treatment of vascular disease (cardiovascular, peripheral 
vascular, and neurovascular).  The two companies have 
complementary research and development programs which 
should enhance our ability to innovate within the broad spectrum 
of interventional medicine."

"Target Therapeutics will become a separate business unit of 
Boston Scientific and will continue to be headquartered 
in Fremont, California."

Gary Bang, President and Chief Executive Officer of 
Target Therapeutics, added, "The strategic fit with Boston 
Scientific is obvious.  Boston Scientific is clearly a global 
leader in less invasive medicine.  Interventional neuroradiology 
continues to emerge as a significant segment of less invasive 
medicine.  The combined resources of the two companies 
will allow for an acceleration in the development of new and 
even more advanced technologies."

The merger is expected to close during the second calendar 
quarter of 1997 and is subject to the approval of shareholders 
of Target Therapeutics and regulatory approval.  Goldman, 
Sachs & Co. is serving as financial advisors to Target Therapeutics 
and has issued a fairness opinion to the Target Therapeutics 
board of directors with respect to the proposed combination.  
Lehman Brothers is serving as financial advisors to Boston 
Scientific.  It is anticipated that the combination will be 
accounted for as a pooling-of-interests.

Boston Scientific is a worldwide developer, manufacturer 
and marketer of medical devices whose products are used 
in a broad range of interventional medical specialties.

Contact:
Larry Best
Boston Scientific Corporation
508-650-8450

Robert E. McNamara
Target Therapeutics, Inc.
510-440-7644